DK358875A - - Google Patents

Info

Publication number
DK358875A
DK358875A DK358875A DK358875A DK358875A DK 358875 A DK358875 A DK 358875A DK 358875 A DK358875 A DK 358875A DK 358875 A DK358875 A DK 358875A DK 358875 A DK358875 A DK 358875A
Authority
DK
Denmark
Application number
DK358875A
Other languages
Danish (da)
Other versions
DK139101C (xx
DK139101B (da
Inventor
C Casagrande
G Ferrari
Original Assignee
Siphar S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siphar S A filed Critical Siphar S A
Publication of DK358875A publication Critical patent/DK358875A/da
Publication of DK139101B publication Critical patent/DK139101B/da
Application granted granted Critical
Publication of DK139101C publication Critical patent/DK139101C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK358875AA 1974-08-08 1975-08-07 Analogifremgangsmåde til fremstilling af 3beta,14beta-dihydroxy-17beta-(4-pyridazinyl)-5beta-androstan-forbindelser. DK139101B (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1085574A CH621803A5 (xx) 1974-08-08 1974-08-08

Publications (3)

Publication Number Publication Date
DK358875A true DK358875A (xx) 1976-02-09
DK139101B DK139101B (da) 1978-12-18
DK139101C DK139101C (xx) 1979-05-21

Family

ID=4367535

Family Applications (1)

Application Number Title Priority Date Filing Date
DK358875AA DK139101B (da) 1974-08-08 1975-08-07 Analogifremgangsmåde til fremstilling af 3beta,14beta-dihydroxy-17beta-(4-pyridazinyl)-5beta-androstan-forbindelser.

Country Status (12)

Country Link
US (1) US4000125A (xx)
JP (1) JPS5141372A (xx)
AR (1) AR217617A1 (xx)
BE (1) BE832271A (xx)
CA (1) CA1049499A (xx)
CH (1) CH621803A5 (xx)
DE (1) DE2534981A1 (xx)
DK (1) DK139101B (xx)
ES (1) ES440110A1 (xx)
FR (1) FR2281124A1 (xx)
GB (1) GB1484655A (xx)
SE (1) SE418401B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144136B (it) * 1980-03-05 1986-10-29 Zenyaku Kogyo Kk Glucosidi di condurango agenti antitumorali che li comprendono e procedimento per la loro preparazione
US5373095A (en) * 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
IT1262931B (it) * 1992-01-16 1996-07-22 Zambon Spa Composti steroidei 17(piridazin-n-ossido)-sostituiti attivi sul sistema cardiovascolare
DE4227616C2 (de) * 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
US20100047338A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
PT1853619E (pt) * 2005-03-02 2011-01-03 Univ Maryland 3-beta-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno para utilização no tratamento de uma doença da próstata
US20110105445A1 (en) * 2008-03-12 2011-05-05 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
CA2770092A1 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3313858B1 (en) * 2015-06-29 2019-09-25 Universiteit Gent Methods for the site-selective coupling of a first agent to a second agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838163A (en) * 1968-11-22 1974-09-24 Hoffmann La Roche Substituted isoxazole derivatives as steroid intermediates

Also Published As

Publication number Publication date
SE7508908L (sv) 1976-02-09
AR217617A1 (es) 1980-04-15
FR2281124A1 (fr) 1976-03-05
DE2534981A1 (de) 1976-02-19
JPS5141372A (xx) 1976-04-07
DK139101C (xx) 1979-05-21
CA1049499A (en) 1979-02-27
GB1484655A (en) 1977-09-01
BE832271A (fr) 1975-12-01
SE418401B (sv) 1981-05-25
FR2281124B1 (xx) 1980-05-16
US4000125A (en) 1976-12-28
ES440110A1 (es) 1977-02-16
CH621803A5 (xx) 1981-02-27
DK139101B (da) 1978-12-18

Similar Documents

Publication Publication Date Title
DK358875A (xx)
CH577999A5 (xx)
BG19682A1 (xx)
BG19713A1 (xx)
BG19746A1 (xx)
BG20244A1 (xx)
BG20501A1 (xx)
BG20746A1 (xx)
BG20884A1 (xx)
BG21136A2 (xx)
BG21312A1 (xx)
AU482019A (xx)
BG21710A1 (xx)
BG22303A1 (xx)
BG22518A1 (xx)
CH1340175A4 (xx)
CH1446574A4 (xx)
CH231275A4 (xx)
CH238674A4 (xx)
CH563833A5 (xx)
CH566532A5 (xx)
CH569333A5 (xx)
CH570549A5 (xx)
CH571710A5 (xx)
CH572263A5 (xx)